SS Innovations Reports Record Q2 Revenue, Bolstering SSi Mantra's Global Expansion

SS Innovations International Inc. (NASDAQ: SSII) has announced record second-quarter revenue of $13.9 million, a 39.4% increase year-over-year, signaling continued momentum for its SSi Mantra surgical robotic platform. The company's first-half revenue reached $25.0 million, up 65.6% from the same period in 2025, underscoring a robust growth trajectory that is capturing the attention of the medical technology sector.

This financial performance is driven by a 30.4% rise in SSi Mantra installations, with 30 systems deployed during the quarter. The installed base now stands at 224 systems across 12 countries, with a cumulative 12,272 surgeries performed. This expansion reflects a growing global demand for minimally invasive surgical options, particularly in regions where access to advanced robotic surgery has been limited.

The company's strategic focus on regulatory milestones could be transformative. SS Innovations is targeting FDA clearance by the first quarter of 2027 and EU CE marking by the end of 2026. Achieving these certifications would open the door to the lucrative U.S. and European markets, potentially accelerating adoption and revenue growth. For the medical device industry, this represents a competitive challenge to established players, as SSi Mantra offers a more cost-effective alternative without compromising on surgical precision.

Beyond financial metrics, the company's telesurgery achievements are extending the clinical profile of SSi Mantra. By enabling remote surgical procedures, the platform can bridge geographic gaps, allowing expert surgeons to operate on patients in underserved areas. This capability has profound implications for global healthcare, potentially democratizing access to high-quality surgical care.

The gross profit for the quarter increased 20.0% to $7.1 million, though gross margin declined to 50.9% from 59.1% in the year-earlier quarter. This margin compression is likely due to increased investment in scaling operations and expanding the installed base. For investors, the focus remains on the company's ability to maintain growth while managing costs, especially as it prepares for regulatory submissions.

The company's performance is a testament to the increasing acceptance of robotic-assisted surgery, a market projected to grow significantly in the coming years. As SS Innovations continues to expand its footprint, the implications for the industry are clear: innovation and affordability are key drivers in reshaping the surgical landscape. With a strong first half and a pipeline of regulatory catalysts, SS Innovations is positioning itself as a major player in the global surgical robotics arena.

For more details on SS Innovations' quarterly results, visit the company's newsroom at https://nnw.fm/zxrT1. Additional updates can be found at https://nnw.fm/SSII.